subject: Biomarkers In Drug Discovery - Optimizing Drug Discovery Timeline And Costs [print this page] Summary Summary
The leading business intelligence provider, has released its latest research, Biomarkers In Drug Discovery - Optimizing Drug Discovery Timeline and Costs. The report provides an in-depth analysis of the potential applications of biomarkers in pharmaceutical drug discovery and clinical services. This pharmaceutical and healthcare report suggests investment decisions in biomarker-based drug research by providing information on valid biomarkers, pipelines, case studies, competitive landscape, geographical trends, mergers and acquisitions and market potential. It also provides an analysis on the trends prevailing in the global biomarkers market. In addition to this, the report covers drivers and restrains for the global biomarkers market.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.
Scope
The scope of this report includes:
- Market Potential and Pipeline Analysis of biomarkers by phase of development, therapeutic class and geography.
- Market Size and forecast of global biomarkers market and biomarkers drug discovery market from 2000 to 2008, forecast forward to 2015.
- Analysis of Key geographies including the US (United States), Europe the UK (United Kingdom), France, Germany, Italy and Spain), Australia and Southeast Asia.
- Investments and Funding Analysis for top companies (Quest Diagnostics, Applied Biosystems, Vermillion, BGMedical, Menarini, Abbott, Roche, Genetech, Affymetrix and Amgen) in the biomarker-based assay development arena. This includes biomarker research on the application and development of novel biomarkers by the top companies and analysis of the competitive factors affecting the global biomarkers market.
- Qualitative analysis of market drivers, market trends, and challenges.
- M&A landscape in the biomarkers space segmented by deal value, geography and phase.
